Background: Hyperdense arteries in cranial CT of acute stroke patients have been described as a sign for acute ischemia in various brain-feeding arteries. However, only 1 case of a hyperdense anterior cerebral artery sign (HACAS) has been published to date. In this study, the frequency and association of HACAS with clinical symptoms and outcome are described. Methods: Our radiological databases were searched for patients with infarcts in the territory of the anterior cerebral artery (ACA). Only patients who received an initial CT and a follow-up CT or MRI were included. The presence of a HACAS was rated by 2 independent observers using the Cohen κ-statistics. Further data recorded were early ischemic signs, final size of infarct, symptoms, initial NIHSS (National Institute of Health Stroke Scale) score, latency between symptom onset and initial CT, etiology, modified Rankin Scale (mRS) score at discharge and secondary hemorrhage. Results: A HACAS could be visualized in 11/24 patients (46%). Interobserver agreement was substantial with Cohen’s κ = 0.66. Patients with a HACAS had a significantly higher NIHSS score (9.45 ± 8.41; median: 8) than those without (3.69 ± 2.09; median: 4). A HACAS was visible more frequently when the CT was performed early (<2.5 h after symptom onset). There was no correlation with single symptoms, size of infarct, etiology, mRS or the tendency to hemorrhage. Conclusions: HACAS is associated with a higher NIHSS score. It is an early sign of ischemia which can be reversible over time. It can be helpful in the detection of ischemia in the territory of the ACA.

Keywords:
Computer tomography, Acute ischemic stroke, Hyperdense artery, Anterior cerebral artery
1.
Ozdemir O, Leung A, Bussiére M, Hachinski V, Pelz D: Hyperdense internal carotid artery sign: a CT sign of acute ischemia. Stroke 2008;39:2011–2016.
2.
Leys D, Pruvo JP, Godefroy O, Rondepierre P, Leclerc X: Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke 1992;23:317–324.
3.
Barber PA, Demchuk AM, Hudon ME, Pexman JH, Hill MD, Buchan AM: Hyperdense sylvian fissure MCA ‘dot’ sign: a CT marker of acute ischemia. Stroke2001;32:84–88.
4.
Krings T, Noelchen D, Mull M, et al: The hyperdense posterior cerebral artery sign: a computed tomography marker of acute ischemia in the posterior cerebral artery territory. Stroke 2006;37:399–403.
5.
Goldmakher GV, Camargo EC, Furie KL, et al: Hyperdense basilar artery sign on unenhanced CT predicts thrombus and outcome in acute posterior circulation stroke. Stroke 2009;40:134–139.
6.
Manelfe C, Larrue V, von Kummer R, et al: Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. Stroke 1999;30:769–772.
7.
von Kummer R, Meyding-Lamade U, Forsting M, et al: Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol 1994;15:9–15.
8.
Tomsick T, Brott T, Barsan W, et al: Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol 1996;17:79–85.
9.
del Saz-Saucedo P, Maestre-Moreno JF, Vatz KA, et al: Sign of hyperdense and hyperintense anterior cerebral artery. Neurologia 2007;22:184–186.
10.
Rutgers DR, van der Grond J, Jansen GH, Somford DM, Mali WP: Radiologic-pathologic correlation of the hyperdense middle cerebral artery sign: a case report. Acta Radiol 2001;42:467–469.
11.
New PF, Aronow S: Attenuation measurements of whole blood and fractions in computed tomography. Radiology 1976;121:635–640.
12.
Brott TG, Adams HP Jr, Olinger CP, et al: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864–870.
13.
Bonita R, Beaglehole R: Modification of Rankin Scale: recovery of motor function after stroke. Stroke 1988;19:1497–1500.
14.
Kang SY, Kim J: Anterior cerebral artery infarction: stroke mechanism and clinical-imaging study in 100 patients. Neurology 2008;70:2386–2393.
15.
Kumral E, Bayulkem G, Evyapan D, Yunten N: Spectrum of anterior cerebral artery territory infarction: clinical and MRI findings. Eur J Neurol 2002;9:615–624.
16.
Bushi D, Grad Y, Einav S, Yodfat O, Nishri B, Tanne D: Hemodynamic evaluation of embolic trajectory in an arterial bifurcation: an in vitro experimental model. Stroke 2005;36:2696–2700.
17.
Minagar A, David NJ: Bilateral infarction in the territory of the anterior cerebral arteries. Neurology 1999;52:886–888.
18.
Kim EY, Lee SK, Kim DJ, et al: Detection of thrombus in acute ischemic stroke: value of thin-section noncontrast-computed tomography. Stroke 2005;36:2745–2747.
19.
Kirchhof K, Welzel T, Mecke C, Zoubaa S, Sartor K: Differentiation of white, mixed, and red thrombi: value of CT in estimation of the prognosis of thrombolysis – phantom study. Radiology 2003;228:126–130.
20.
Schuknecht B, Ratzka M, Hofmann E: The ‘dense artery sign’: major cerebral artery thromboembolism demonstrated by computed tomography. Neuroradiology 1990;32:98–103.
21.
National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study Group: Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 2000;31:2912–2919.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.